Thread: Cancer drug potential for reducing a-synuclien aggregates
View Single Post
Old 10-03-2016, 10:06 AM
olsen's Avatar
olsen olsen is offline
Senior Member
  
Join Date: Aug 2006
Posts: 1,860
15 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
Default Cancer drug potential for reducing a-synuclien aggregates
A new protein capable of reducing the risk of Parkinson's disease identified | TheHealthSite.com


LAG3 inhibitor made by Norvartis is in Phase 1/2 clinical trial for solid tumor cancers.

Beyond PD-1[mdash]selected immuno-oncology drug therapies in development : Immuno-oncology moves beyond PD-1 : Nature Biotechnology : Nature Research
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here — it's just not very evenly distributed. William Gibson
olsen is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
eds195 (10-03-2016), jeffreyn (10-03-2016)